Serkan Ünal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Serkan Ünal has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Özgür Mehtap
Kocaeli University Faculty of Medicine, Department of Hematology, Kocaeli, Türkiye
6 shared publications - Abdullah Hacihanefioglu
Kocaeli University Faculty of Medicine, Department of Hematology, Kocaeli, Türkiye
5 shared publications - Ayfer Gedük
Faculty of Medicine Hematology Clinic, Kocaeli University, Kocaeli 41380, Türkiye
5 shared publications - Pınar Tarkun
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kocaeli University, 41001 Kocaeli, Turkey
5 shared publications - Sinan Mersin
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Mersin University, 33110 Mersin, Türkiye
5 shared publications - Kemal Aygün
Division of Hematology, İzmir Atatürk Training and Research Hospital, İzmir 35360, Türkiye
4 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 184-185
Spontaneous Hematotympanum in a Chronic Lymphocytic Leukemia Patient Receiving Ibrutinib: A Rare Bleeding Complication
- 2 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 184-185
Open AccessSpontaneous Hematotympanum in a Chronic Lymphocytic Leukemia Patient Receiving Ibrutinib: A Rare Bleeding Complication
- Open Access
- 12 March 2026
- Published by Kastamonu University in Kastamonu Medical Journal
- Vol. 6 (1) , 98-100
Efficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient
Acute myeloid leukemia (AML) is a myeloid malignancy characterized by relentless proliferation of immature myeloid blasts. Myelodysplastic Syndrome (MDS)-related Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the transformation of myelodysplastic cells into an aggressive form of leukemia, marked by uncontrolled proliferation of abnormal myeloid precursors and impaired hematopoiesis. This case report delves into the intricate management and prolonged clinical success of a 77-year-old male diagnosed with MDS-related AML featuring monosomy 7, severe left ventricular ejection fraction (LVEF) heart failure, and chronic renal disease. Despite challenging laboratory findings at diagnosis and unfavorable monosomy 7 cytogenetics, the patient achieved an unexpectedly positive outcome following treatment with 5-azacytidine.This intricate case presentation not only highlights the challenges posed by advanced age, chronic disease-specific considerations, and the interplay of multiple comorbidities but also underscores the potential for tailored therapeutic interventions to transcend conventional prognostic expectations and yield prolonged clinical success.
- 12 March 2026
- Published by Kastamonu University in Kastamonu Medical Journal
- Vol. 6 (1) , 98-100
Open AccessEfficacy of 5-azacytidine in myelodysplastic syndrome (MDS)-related acute myeloid leukemia (AML) with monosomy 7: prolonged clinical success in an elderly patient
Acute myeloid leukemia (AML) is a myeloid malignancy characterized by relentless proliferation of immature myeloid blasts. Myelodysplastic Syndrome (MDS)-related Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the transformation of myelodysplastic cells into an aggressive form of leukemia, marked by uncontrolled proliferation of abnormal myeloid precursors and impaired hematopoiesis. This case report delves into the intricate management and prolonged clinical success of a 77-year-old male diagnosed with MDS-related AML featuring monosomy 7, severe left ventricular ejection fraction (LVEF) heart failure, and chronic renal disease. Despite challenging laboratory findings at diagnosis and unfavorable monosomy 7 cytogenetics, the patient achieved an unexpectedly positive outcome following treatment with 5-azacytidine.This intricate case presentation not only highlights the challenges posed by advanced age, chronic disease-specific considerations, and the interplay of multiple comorbidities but also underscores the potential for tailored therapeutic interventions to transcend conventional prognostic expectations and yield prolonged clinical success.
- Open Access
- 4 February 2025
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 3 (1) , 18-19
Comprehensive management of concurrent chronic lymphocytic leukemia (CLL) and evans syndrome: combinating rituximab, venetoclax and eltrombopag
Chronic Lymphocytic Leukemia (CLL) and Evans Syndrome represent complex hematologic disorders characterized by distinct yet interconnected pathophysiologies. This case report explores the diagnostic and therapeutic intricacies of managing concurrent CLL and Evans Syndrome in a 59-year-old male patient presenting with fatigue and petechiae. Laboratory findings revealed severe hematologic derangements indicative of advanced CLL and autoimmune hemolytic anemia (AIHA). The diagnostic journey encompassed bone marrow analysis confirming CLL and Coombs positivity suggesting Evans Syndrome, with careful exclusion of immune thrombocytopenia (ITP). Initial therapeutic interventions included steroids and intravenous immunoglobulin (IVIG) for AIHA, alongside eltrombopag for persistent thrombocytopenia. Subsequently, rituximab and venetoclax were initiated for CLL, leading to complete remission. The successful outcome underscores the importance of an integrated therapeutic approach in managing concurrent CLL and Evans Syndrome, offering insights for future clinical management of complex hematologic disorders.
- 4 February 2025
- Published by MediHealth Academy in Journal of Current Hematology & Oncology Research
- Vol. 3 (1) , 18-19
Open AccessComprehensive management of concurrent chronic lymphocytic leukemia (CLL) and evans syndrome: combinating rituximab, venetoclax and eltrombopag
Chronic Lymphocytic Leukemia (CLL) and Evans Syndrome represent complex hematologic disorders characterized by distinct yet interconnected pathophysiologies. This case report explores the diagnostic and therapeutic intricacies of managing concurrent CLL and Evans Syndrome in a 59-year-old male patient presenting with fatigue and petechiae. Laboratory findings revealed severe hematologic derangements indicative of advanced CLL and autoimmune hemolytic anemia (AIHA). The diagnostic journey encompassed bone marrow analysis confirming CLL and Coombs positivity suggesting Evans Syndrome, with careful exclusion of immune thrombocytopenia (ITP). Initial therapeutic interventions included steroids and intravenous immunoglobulin (IVIG) for AIHA, alongside eltrombopag for persistent thrombocytopenia. Subsequently, rituximab and venetoclax were initiated for CLL, leading to complete remission. The successful outcome underscores the importance of an integrated therapeutic approach in managing concurrent CLL and Evans Syndrome, offering insights for future clinical management of complex hematologic disorders.
- Open Access
- 7 June 2024
- Published by MediHealth Academy in Kastamonu Medical Journal
- Vol. 4 (2) , 78-79
Optimizing patient care: rethinking referrals for iron deficiency anemia in internal medicine
In this letter, we address the prevalent issue of inappropriate referrals of iron deficiency anemia patients to hematologists by internal medicine specialists. Emphasizing that iron deficiency anemia extends beyond hematological boundaries, we advocate for a nuanced understanding among primary care clinicians. By encouraging collaboration with relevant specialties, such as gastroenterology and nutrition, we aim to optimize patient care, alleviate strain on specialized services, and promote a more efficient healthcare system.
- 7 June 2024
- Published by MediHealth Academy in Kastamonu Medical Journal
- Vol. 4 (2) , 78-79
Open AccessOptimizing patient care: rethinking referrals for iron deficiency anemia in internal medicine
In this letter, we address the prevalent issue of inappropriate referrals of iron deficiency anemia patients to hematologists by internal medicine specialists. Emphasizing that iron deficiency anemia extends beyond hematological boundaries, we advocate for a nuanced understanding among primary care clinicians. By encouraging collaboration with relevant specialties, such as gastroenterology and nutrition, we aim to optimize patient care, alleviate strain on specialized services, and promote a more efficient healthcare system.
- Open Access
- 17 December 2023
- Published by MediHealth Academy in Kastamonu Medical Journal
- Vol. 3 (4) , 216-217
Concurrent diagnosis of Sjogren’s syndrome and polycthemia vera: a rare co-existence
Primary Sjogren's Syndrome(pSS) is a chronic autoimmune disease and focal lymphocytic infiltration of the exocrine glands is the key pathological feature (1). Polycythemia vera(PV) is a chronic myeloproliferative disorder characterized by JAK-2 mutations and increased red blood cell mass(2,3). Autoimmune diseases and hematological malignancies can often be observed together. Patients with SS are at a higher risk of developing lymphoproliferative diseases mainly low-grade B-cell lymphomas and predominantly marginal zone lymphoma. Moreover, PV can rarely be presented with paraneoplastic events including small vessel vasculitis (2). However, PV and pSS co-existence had never been reported. We here want to present a case of concurrently diagnosed PV and pSS.
- 17 December 2023
- Published by MediHealth Academy in Kastamonu Medical Journal
- Vol. 3 (4) , 216-217
Open AccessConcurrent diagnosis of Sjogren’s syndrome and polycthemia vera: a rare co-existence
Primary Sjogren's Syndrome(pSS) is a chronic autoimmune disease and focal lymphocytic infiltration of the exocrine glands is the key pathological feature (1). Polycythemia vera(PV) is a chronic myeloproliferative disorder characterized by JAK-2 mutations and increased red blood cell mass(2,3). Autoimmune diseases and hematological malignancies can often be observed together. Patients with SS are at a higher risk of developing lymphoproliferative diseases mainly low-grade B-cell lymphomas and predominantly marginal zone lymphoma. Moreover, PV can rarely be presented with paraneoplastic events including small vessel vasculitis (2). However, PV and pSS co-existence had never been reported. We here want to present a case of concurrently diagnosed PV and pSS.
- Open Access
- 25 March 2023
- Published by Bayburt Universitesi in Bayburt Eğitim Fakültesi Dergisi
- Vol. 18 (37) , 218-240
Ortaöğretim Düzeyindeki Öğrencilerin Dijital Okuryazarlık Düzeyleri Dijital Bağımlılık ve Sanal Ortam Yalnızlık Düzeyleri
Bu araştırmanın amacı ortaöğretim öğrencilerinin dijital okuryazarlık düzeyleri, dijital bağımlılık ve sanal ortam yalnızlık düzeylerinin çeşitli değişkenler açısından betimlenmesidir. Araştırma betimsel tarama modeliyle yürütülmüştür. Araştırmanın çalışma grubunu devlet okullarında öğrenim gören 354 ortaöğretim öğrencileri oluşturmaktadır. Veri toplanmasında Dijital Okuryazarlık Ölçeği, Dijital Bağımlılık Ölçeği ve Sanal Ortam Yalnızlık Ölçeği kullanılmıştır. Elde edilen veriler Anova, T-Testi, ve pearson korelasyon testleri ile incelenmiştir ve şu sonuçlara erişilmiştir: Farklı sınıflarda öğrenim gören öğrencilerin dijital okuryazarlık, dijital bağımlılık ve sanal ortam yalnızlık düzeylerinin benzer düzeydedir. Kız ve erkek öğrencilerin dijital okuryazarlık, dijital bağımlılık ve sanal ortam yalnızlık düzeylerinin benzer düzeydedir. Öğrencilerin dijital okuryazarlık ve dijital bağımlılık düzeyleri arasında doğrusal bir ilişki mevcuttur.
- 25 March 2023
- Published by Bayburt Universitesi in Bayburt Eğitim Fakültesi Dergisi
- Vol. 18 (37) , 218-240
Open AccessOrtaöğretim Düzeyindeki Öğrencilerin Dijital Okuryazarlık Düzeyleri Dijital Bağımlılık ve Sanal Ortam Yalnızlık Düzeyleri
Bu araştırmanın amacı ortaöğretim öğrencilerinin dijital okuryazarlık düzeyleri, dijital bağımlılık ve sanal ortam yalnızlık düzeylerinin çeşitli değişkenler açısından betimlenmesidir. Araştırma betimsel tarama modeliyle yürütülmüştür. Araştırmanın çalışma grubunu devlet okullarında öğrenim gören 354 ortaöğretim öğrencileri oluşturmaktadır. Veri toplanmasında Dijital Okuryazarlık Ölçeği, Dijital Bağımlılık Ölçeği ve Sanal Ortam Yalnızlık Ölçeği kullanılmıştır. Elde edilen veriler Anova, T-Testi, ve pearson korelasyon testleri ile incelenmiştir ve şu sonuçlara erişilmiştir: Farklı sınıflarda öğrenim gören öğrencilerin dijital okuryazarlık, dijital bağımlılık ve sanal ortam yalnızlık düzeylerinin benzer düzeydedir. Kız ve erkek öğrencilerin dijital okuryazarlık, dijital bağımlılık ve sanal ortam yalnızlık düzeylerinin benzer düzeydedir. Öğrencilerin dijital okuryazarlık ve dijital bağımlılık düzeyleri arasında doğrusal bir ilişki mevcuttur.
- Open Access
- 18 January 2023
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 39 (3) , 518
Correction to: Efects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma
[This corrects the article DOI: 10.1007/s12288-022-01574-6.].
- 18 January 2023
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 39 (3) , 518
Open AccessCorrection to: Efects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma
[This corrects the article DOI: 10.1007/s12288-022-01574-6.].
- 17 October 2022
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 39 (2) , 220-227
Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma
Purpose The receptor for advanced glycation end products (RAGE) upregulated during the onset and progression of cancer and bone-related pathologies. In this study, we aimed to investigate the role of serum advanced glycation end products (AGEs), soluble RAGE (sRAGE) and high mobility group box 1 (HMGB1), in multiple myeloma (MM). Methods AGEs, sRAGE and HMGB1 concentrations of 54 newly diagnosed MM patients and 30 healthy volunteers were measured by ELISA. The estimations were done only once at diagnosis. The medical records of the patients were evaluated. Results There was no significant difference between the AGEs and sRAGE levels between the patient and control groups (p = 0.273, p = 0.313). In ROC analysis, a HMGB1 cutoff value of > 9170 pg/ml accurately discriminated MM patients (AUC = 0.672, 95% CI 0.561–0.77, p = 0.0034). AGEs level was found to be significantly higher in early-stage disease and HMGB1 in advanced disease (p = 0.022, p = 0.026). High HMGB1 levels were detected in patients whose with better first-line treatment response (p = 0.019). At 36 months, 54% of patients with low AGE were alive, compared to 79% of patients with high AGE (p = 0.055). Patients with high HMGB1 levels tended to have a longer PFS (median 43 mo [95% CI; 20.68–65.31] ) compared to patients with low HMGB1 levels (median 25 mo [95% CI; 12.39–37.6], p = 0.054). Conclusion In this study, a significant elevation of serum HMGB1 level was found in MM patients. In addition, the positive effects of RAGE ligands on treatment response and prognosis were determined.
- 17 October 2022
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 39 (2) , 220-227
Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma
Purpose The receptor for advanced glycation end products (RAGE) upregulated during the onset and progression of cancer and bone-related pathologies. In this study, we aimed to investigate the role of serum advanced glycation end products (AGEs), soluble RAGE (sRAGE) and high mobility group box 1 (HMGB1), in multiple myeloma (MM). Methods AGEs, sRAGE and HMGB1 concentrations of 54 newly diagnosed MM patients and 30 healthy volunteers were measured by ELISA. The estimations were done only once at diagnosis. The medical records of the patients were evaluated. Results There was no significant difference between the AGEs and sRAGE levels between the patient and control groups (p = 0.273, p = 0.313). In ROC analysis, a HMGB1 cutoff value of > 9170 pg/ml accurately discriminated MM patients (AUC = 0.672, 95% CI 0.561–0.77, p = 0.0034). AGEs level was found to be significantly higher in early-stage disease and HMGB1 in advanced disease (p = 0.022, p = 0.026). High HMGB1 levels were detected in patients whose with better first-line treatment response (p = 0.019). At 36 months, 54% of patients with low AGE were alive, compared to 79% of patients with high AGE (p = 0.055). Patients with high HMGB1 levels tended to have a longer PFS (median 43 mo [95% CI; 20.68–65.31] ) compared to patients with low HMGB1 levels (median 25 mo [95% CI; 12.39–37.6], p = 0.054). Conclusion In this study, a significant elevation of serum HMGB1 level was found in MM patients. In addition, the positive effects of RAGE ligands on treatment response and prognosis were determined.
- 17 December 2021
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 17 (4) , 367-374
Are Platelet-related Parameters Predictive of the Prognosis of Hodgkin’s Lymphoma?
- 17 December 2021
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 17 (4) , 367-374
Are Platelet-related Parameters Predictive of the Prognosis of Hodgkin’s Lymphoma?
- Open Access
- 4 May 2021
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 38 (3) , 211-217
The Evaluation of Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
Constantly increasing health expenditures lead use of generic molecules and generics of bortezomib have been used for a long time. The aim of this study is to retrospectively examine the effectiveness, side effects and reliability of generic bortezomib in newly diagnosed multiple myeloma (MM) patients. The data of 95 patients who received four cycles of bortezomib as a first- or second-line therapy in a single center were retrospectively recorded. Treatment responses, side effects and progression free survival (PFS) rates have been calculated and compared. Of the 95 patients, 42 used the original and 53 used the generic molecule. Epidemiological data, MM types, genetic risk groups, laboratory values at diagnosis and bortezomib treatment lines (as a first line or second) were evaluated, and there was no statistical difference between the two groups. When the response rates were evaluated with International Myeloma Working Group (IMWG) criteria, there were no significant difference (p: 0,42). Partial response (PR) and above response rates were similar (%81 vs %79,2 p:0,836). PFS values were 42.8 months in the original and 37.8 months in the generic molecule group (p: 0,68). Side effects were seen in 44,2% of patients, and the most common side effects were neuropathy, cytopenias and infections. They were similar in both groups (p: 0,67). Although this retrospective study is limited, it is the first study comparing the original molecule of bortezomib with its generic. There was no statistical difference between the two groups in terms of treatment responses, PFS times and side effects. However, large-scale evaluations can help obtain healthier data on this subject.
- 4 May 2021
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 38 (3) , 211-217
Open AccessThe Evaluation of Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
Constantly increasing health expenditures lead use of generic molecules and generics of bortezomib have been used for a long time. The aim of this study is to retrospectively examine the effectiveness, side effects and reliability of generic bortezomib in newly diagnosed multiple myeloma (MM) patients. The data of 95 patients who received four cycles of bortezomib as a first- or second-line therapy in a single center were retrospectively recorded. Treatment responses, side effects and progression free survival (PFS) rates have been calculated and compared. Of the 95 patients, 42 used the original and 53 used the generic molecule. Epidemiological data, MM types, genetic risk groups, laboratory values at diagnosis and bortezomib treatment lines (as a first line or second) were evaluated, and there was no statistical difference between the two groups. When the response rates were evaluated with International Myeloma Working Group (IMWG) criteria, there were no significant difference (p: 0,42). Partial response (PR) and above response rates were similar (%81 vs %79,2 p:0,836). PFS values were 42.8 months in the original and 37.8 months in the generic molecule group (p: 0,68). Side effects were seen in 44,2% of patients, and the most common side effects were neuropathy, cytopenias and infections. They were similar in both groups (p: 0,67). Although this retrospective study is limited, it is the first study comparing the original molecule of bortezomib with its generic. There was no statistical difference between the two groups in terms of treatment responses, PFS times and side effects. However, large-scale evaluations can help obtain healthier data on this subject.